Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

    July 2023 in “ Cancers ”
    Pietro Sollena, Vasiliki Nikolaou, Ηλίας Κοττέας … Ketty Peris
    Studysummary In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Art of Prevention: The Importance of Dermatologic Care When Using Aromatase Inhibitors International Journal of Women’s Dermatology · 2021
    2. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer JAMA Dermatology · 2018
    3. Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis Expert Review of Anticancer Therapy · 2017
    4. Alopecia With Endocrine Therapies in Patients With Cancer Oncologist · 2013

    Related research 1

    1. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study Cancers · 2023